NeuroMetrix
NeuroMetrix
NURO
NASDAQ
4.35
USD
0.00%
About
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems.
The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment.
Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 12.4K |
| Three Month Average Volume | 307.1K |
| High Low | |
| Fifty-Two Week High | 6.3992 USD |
| Fifty-Two Week Low | 2.66 USD |
| Fifty-Two Week High Date | 12 Sep 2023 |
| Fifty-Two Week Low Date | 13 Aug 2024 |
| Price and Volume | |
| Current Price | 3.82 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 4.57% |
| Thirteen Week Relative Price Change | -6.81% |
| Twenty-Six Week Relative Price Change | -13.58% |
| Fifty-Two Week Relative Price Change | -45.94% |
| Year-to-Date Relative Price Change | -10.39% |
| Price Change | |
| One Day Price Change | -1.56% |
| Thirteen Week Price Change | -0.26% |
| Twenty-Six Week Price Change | -4.98% |
| Five Day Price Change | 8.22% |
| Fifty-Two Week Price Change | -32.26% |
| Year-to-Date Price Change | 6.11% |
| Month-to-Date Price Change | 4.95% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 13.17515 USD |
| Book Value Per Share (Most Recent Quarter) | 8.58491 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 13.17515 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 8.58491 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.84866 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 5.66361 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.90604 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -6.26636 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.504 USD |
| Normalized (Last Fiscal Year) | -6.27295 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -6.26636 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.504 USD |
| Including Extraordinary Items (Last Fiscal Year) | -6.26636 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.504 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 11.80188 USD |
| Cash Per Share (Most Recent Quarter) | 8.14759 USD |
| Cash Flow Per Share (Last Fiscal Year) | -6.2129 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -5.20447 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.73451 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -50 |
| Cash Flow Revenue (Trailing Twelve Months) | -163 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -181.03% |
| Pretax Margin (Last Fiscal Year) | -110.64% |
| Pretax Margin (5 Year) | -48.88% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 66.89% |
| Gross Margin (Trailing Twelve Months) | 60.19% |
| Gross Margin (5 Year) | 59.17% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -121.18% |
| Operating Margin (Trailing Twelve Months) | -203.04% |
| Operating Margin (5 Year) | -51.43% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -110.64% |
| Net Profit Margin (Trailing Twelve Months) | -181.03% |
| Net Profit Margin (5 Year) | -48.88% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -27.57% |
| Tangible Book Value (5 Year) | 26.93% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -53.55% |
| Revenue Growth (3 Year) | -18.18% |
| Revenue Change (Trailing Twelve Months) | -39.08% |
| Revenue Per Share Growth | -42.83% |
| Revenue Growth (5 Year) | -7.17% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 5.03% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 52.32% |
| EPS Change (Trailing Twelve Months) | 4.37% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -16,429,950 |
| Net Debt (Last Fiscal Year) | -17,997,160 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 16 |
| Quick Ratio (Most Recent Quarter) | 11 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 17 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,268,410 |
| Free Cash Flow (Trailing Twelve Months) | -7,141,790 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -28.33% |
| Return on Assets (Trailing Twelve Months) | -38.06% |
| Return on Assets (5 Year) | -23.24% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -30.06% |
| Return on Equity (Trailing Twelve Months) | -40.99% |
| Return on Equity (5 Year) | -28.31% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -29.85% |
| Return on Investment (Trailing Twelve Months) | -40.80% |
| Return on Investment (5 Year) | -27.26% |